Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
ACCELERON PHARMA INC (XLRN) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/04/2021 8-K Quarterly results
Docs: "Acceleron Reports Third Quarter 2021 Financial Results - Acceleron recognized approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of REBLOZYL® -"
05/06/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Acceleron Reports Third Quarter 2020 Operating and Financial Results - Acceleron recognized approximately $19.3 million in royalty revenue for Q3 2020 from approximately $96 million in net sales of REBLOZYL® -"
08/06/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
02/27/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
08/05/2019 8-K Quarterly results
05/09/2019 8-K Quarterly results
Docs: "Acceleron Reports First Quarter 2019 Operating and Financial Results – Luspatercept Biologics License Application and Marketing Authorization Application submitted in April 2019 – – Part 2 results from the ACE-083 Phase 2 trials in facioscapulohumeral muscular dystrophy expected in the second half of 2019 and Charcot-Marie-Tooth disease anticipated in Q1 2020 – – PULSAR and SPECTRA Phase 2 trials of sotatercept in pulmonary arterial hypertension on track with topline results expected from PULSAR in 1H 2020 – Cambridge, Mass. – May 9, 2019 – Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the first quarter ..."
02/27/2019 8-K Quarterly results
10/30/2018 8-K Quarterly results
Docs: "Acceleron Reports Third Quarter 2018 Operating and Financial Results – MEDALIST and BELIEVE Phase 3 trial results in myelodysplastic syndromes and beta-thalassemia, respectively, are expected to be presented at the 60th American Society of Hematology Annual Meeting – – COMMANDS Phase 3 trial in patients with lower-risk MDS who are treatment naïve has been initiated – – Part 1 results from the ACE-083 Phase 2 trial in facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth disease were presented at the World Muscle Society Annual Meeting – – Pulmonary Arterial Hypertension R&D Deep Dive Event scheduled for Friday, November 16th in New York City – Cambridge, Mass. – October 30, 2018 – Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of ..."
08/02/2018 8-K Quarterly results
Docs: "Acceleron Reports Second Quarter 2018 Operating and Financial Results – MEDALIST and BELIEVE Phase 3 trials met all primary and key secondary endpoints – – ACE-083 Part 2 of the Phase 2 trials in facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth disease are underway – – PULSAR Phase 2 trial initiated with sotatercept in pulmonary arterial hypertension – Cambridge, Mass. – August 2, 2018 – Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2018. “We have had a very successful start to 2018, and we look forward to carrying this momentum forward throughout the rest of the year ..."
05/08/2018 8-K Quarterly results
Docs: "Acceleron Reports First Quarter 2018 Operating and Financial Results – Top-line results from the MEDALIST and BELIEVE Phase 3 trials of luspatercept expected in mid-2018 – – ACE-083 advances into Part 2 of the ongoing Phase 2 trial in facioscapulohumeral muscular dystrophy – – PULSAR Phase 2 trial with sotatercept in pulmonary arterial hypertension on track to initiate in Q2 2018 – Cambridge, Mass. – May 8, 2018 – Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2018. “2018 is an important year for our Company, as we prepare for the upcoming top-line results from our MEDALIST and BELIE..."
02/27/2018 8-K Quarterly results
Docs: "Acceleron Reports Fourth Quarter and Full Year 2017 Operating and Financial Results - Top-line results from the MEDALIST and BELIEVE Phase 3 trials of luspatercept are expected in mid-2018 - - Plans to advance neuromuscular agent ACE-083 into Part 2 of the ongoing Phase 2 trials in facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease - - Expanded pipeline with sotatercept in pulmonary disease; on track to initiate a Phase 2 trial in pulmonary arterial hypertension in 1H 2018 -"
11/07/2017 8-K Quarterly results
Docs: "Acceleron Pharma Reports Third Quarter 2017 Operational and Financial Results - Presented vision and strategic focus in hematological, neuromuscular, and pulmonary diseases at September R&D Day - - Obtained the rights to fund, develop, and lead global commercialization of sotatercept in pulmonary arterial hypertension; robust preclinical results show potential for first-in-class disease modifying approach -"
08/03/2017 8-K Quarterly results
Docs: "Acceleron Pharma Reports Second Quarter 2017 Operational and Financial Results - Completed full enrollment of luspatercept MEDALIST and BELIEVE Phase 3 trials - - Presented updated luspatercept Phase 2 results in patients with MDS and beta-thalassemia receiving treatment for up to two years - - Treated first patient in ACE-083 Phase 2 study in Charcot-Marie-Tooth disease - - Upcoming R&D Day on September 19 th to highlight Acceleron’s pipeline and strategic focus - Cambridge, Mass. – August 3, 2017 – Acceleron Pharma Inc. , a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2..."
05/08/2017 8-K Form 8-K - Current report
03/01/2017 8-K Form 8-K - Current report
11/03/2016 8-K Quarterly results
Docs: "Consulting Agreement, by and between John L. Knopf, Ph.D. and Acceleron Pharma Inc.",
"Acceleron Pharma Reports Third Quarter 2016 Financial and Operational Results - Appointed Habib Dable as President and CEO effective December 1, 2016 - - Five upcoming presentations at American Society of Hematology Annual Meeting in December - - Advancing ACE-083 into Phase 2 study for facioscapulohumeral muscular dystrophy - - Maintained strong balance sheet with $251 million in cash to fund projected operating requirements into the second half of 2019 - Cambridge, Mass. – November 3, 2016 – Acceleron Pharma Inc. , a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2016..."
08/04/2016 8-K Quarterly results
Docs: "Acceleron Pharma Reports Second Quarter 2016 Financial and Operational Results - Presented positive data that confirms and extends longer term Phase 2 safety and efficacy results for luspatercept in myelodysplastic syndromes and beta-thalassemia - - Presented positive Phase 1 ACE-083 results showing increases in muscle volume in the tibialis anterior muscle in healthy volunteers - Cambridge, Mass. – August 4, 2016 – Acceleron Pharma Inc. , a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of highly innovative therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2016. “In the second quarter, we presented updated luspatercept data that builds..."
05/05/2016 8-K Form 8-K - Current report
02/25/2016 8-K Quarterly results
Docs: "Acceleron Pharma Reports Fourth Quarter and Year Ended 2015 Financial and Operational Results and Recent Highlights - Initiated Phase 3 trials with luspatercept in MDS and beta-thalassemia with partner Celgene - - Received Fast Track Designation for luspatercept in MDS and beta-thalassemia, and for dalantercept in RCC - - Presented initial Phase 1 results for ACE-083, a locally acting therapeutic candidate for muscle diseases - - Introduced ACE-2494, Acceleron's first IntelliTrap™ molecule, a therapeutic candidate for systemic muscle diseases - - Raised $150 million in gross proceeds to advance wholly owned programs, including locally acting and systemic agents for muscle diseases -"
11/04/2015 8-K Quarterly results
Docs: "Acceleron Pharma Reports Third Quarter 2015 Financial and Operational Results – ACE-083 Phase 1 results demonstrate an unprecedented increase in muscle volume. Phase 2 clinical trials planned to start next year – – ACE-2494 generates significant increases in muscle mass in preclinical studies. Phase 1 clinical trial of ACE-2494 planned to start next year – – FDA granted Fast Track Designation for dalantercept in combination with axitinib for the treatment of patients with advanced renal cell carcinoma – – Phase 3 clinical trials with luspatercept in lower risk myelodysplastic syndromes and beta-thalassemia expected to begin by year-end 2015 – Cambridge, Mass. – November 4, 2015 – Acceleron Pharma Inc. , a clinical stage biopharmaceutical company focused on the discovery, development and co..."
08/06/2015 8-K Quarterly results
Docs: "Acceleron Pharma Reports Second Quarter 2015 Financial and Operational Results – Completed luspatercept myelodysplastic syndromes phase 2 clinical trial – – FDA Fast Track Designations granted to luspatercept for the treatment of patients with beta-thalassemia – – Phase 3 clinical trials with luspatercept in lower risk myelodysplastic syndromes and beta-thalassemia expected to begin by year-end 2015 –"
05/07/2015 8-K Quarterly results
Docs: "Acceleron Pharma Reports First Quarter 2015 Financial and Operational Results – Luspatercept phase 2 data showed encouraging activity in lower risk myelodysplastic syndromes patients – – Celgene and Acceleron selected luspatercept to advance into Phase 3 programs in MDS and beta-thalassemia by year-end – – Promising data from dalantercept phase 2 clinical trial in patients with renal cell carcinoma presented at ASCO-GU conference – Cambridge, Mass. – May 7, 2015 – Acceleron Pharma Inc. , a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today provided a corporate update and reported financial results for the first quarter ended March 31, 2015. “Acceleron’s clinical..."
03/02/2015 8-K Quarterly results
Docs: "Acceleron Pharma Reports Fourth Quarter and Year Ended 2014 Financial and Operational Results"
11/07/2014 8-K Quarterly results
Docs: "Acceleron Pharma Reports Third Quarter 2014 Financial and Operational Results – Phase 2 data from beta-thalassemia and MDS trials selected for oral presentations at ASH – – Phase 2 data from end-stage renal disease trial to be presented at ASN – – Initiated final stage of beta-thalassemia and MDS phase 2 clinical trials – – Innovative muscle drug now in human clinical trials – Cambridge, Mass. – November 7, 2014 – Acceleron Pharma Inc. , a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2014. “Over the next few weeks, we are poised to share new data from several ongoing cli..."
08/12/2014 8-K Quarterly results
Docs: "Acceleron Pharma Reports Second Quarter 2014 Financial Results -- Encouraging interim data presented from five phase 2 clinical trials -- -- Two additional phase 2 studies initiated -- -- Pipeline advancement and expansion demonstrate potential value of late-stage clinical opportunities -- Cambridge, Mass. – August 12, 2014 – Acceleron Pharma Inc. , a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2014. “This has been a period of tremendous momentum at Acceleron with the rapid progress and expansion of our clinical pipeline,” said John Knopf, Ph.D., Chief Executive Officer of ..."
05/15/2014 8-K Quarterly results
Docs: "Acceleron Pharma Reports First Quarter 2014 Financial Results"
02/26/2014 8-K Quarterly results
Docs: "Acceleron Pharma Reports Fourth Quarter and Year Ended 2013 Financial Results"
11/06/2013 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy